GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

Delayed gastric emptying in adolescent patients on GLP-1 receptor agonists with standard preoperative fasting guidelines: a prospective cohort study

Design
Prospective cohort · 67 participants · Unknown outcome
Match to healthy normal-weight adults aged 55–75
Different population[Auto] Participants had obesity/overweight (age ≥10).
Could weight loss explain it?
Possibly[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
Study tier
Study tier 3[Auto] Observational design; confounding by indication and healthy-user effects cannot be excluded (auto-provisional).
Assessment
Version 1 · automatic, not yet reviewed by a person · Sep 13, 2026

Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.

[Auto, unreviewed; quoted from abstract conclusions] We observed that 80% of adolescents on GLP1-RAs had solids on gastric ultrasound despite having fasted for over 12 h.

01Findings

What the study reported

Drugs
Class unspecified
Primary outcome
Not extracted
Effect
Not extracted
95% confidence interval
Not extracted
Follow-up
Not stated
Adverse events
Not extracted
Limitations
Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.

Who was studied

Age min
10
Obesity status
obesity/overweight present (all or most)
Diabetes status
diabetes mentioned
Sample size
67

Study quality details

Study design
Prospective cohort
Sample size
67
Randomization
no
Blinding
not stated
Comparator
not stated
Follow up duration
not stated
Outcome type
unknown
Replication
not assessed (auto)
Consistency with other evidence
not assessed (auto)
Population applicability
INDIRECT
Statistical precision
not extracted
Risk of bias
not assessed (auto)
Funding conflicts
unclear
Peer review status
yes
02Funding

Funding and conflicts

Funding
not reported in abstract
Industry funded
Unclear
Manufacturer
None identified
Sponsor role
not reported in abstract
Author conflicts
Declaration of interest The authors declare that they have no conflicts of interest.
Independent replication
unknown

Funding is shown on every study and never used to score it.

04Source

The source, as retrieved

Abstract

[BACKGROUND] Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are approved in patients aged ≥10 yr for type 2 diabetes mellitus and aged ≥12 yr for obesity. We examined the effect of GLP1-RAs on the retention of gastric contents in fasting adolescents. [METHODS] This prospective cohort study examined adolescent patients (10-18 yr) at a single institution between June 2023 and November 2024. Three groups were compared: a GLP1-RA group; a group at-risk for delayed gastric emptying not on GLP1-RAs; and a healthy control group. All patients fasted 8 h for solids and 1 h for clears liquid. Gastric contents were examined utilising gastric ultrasound qualitatively on a 3-point scale, and quantitatively. The primary outcome was the number of adolescents on GLP1-RAs with residual gastric contents (presence of solids or gastric fluid volume ≥1.5 ml kg-1). [RESULTS] In total, 67 patients were analysed: 20 in the GLP1-RA group; 27 in the at-risk group; and 20 in the control group. The median age was 14.8 (interquartile range [IQR] 13.2-16.6) yr, and median fasting durations for solids and clears were 13 h (IQR 12-14) and 12 h (IQR 3.5-13), respectively. In the GLP1-RA group, 16/20 patients (80%) had solids present on gastric ultrasound, compared with 17/27 patients (63%) in the at-risk group and 1/20 patient (5%) in the control group (unadjusted P <0.001; adjusted P <0.02, with propensity score adjustment for age, body mass index, sex, race, and NPO time). [CONCLUSIONS] We observed that 80% of adolescents on GLP1-RAs had solids on gastric ultrasound despite having fasted for over 12 h.

Where this record came from

SourceRetrievedIdentifier
pubmedSep 13, 202642711215
first ingestion